
Opinion|Videos|February 14, 2025
Financial and Operational Considerations of Implementing Biosimilars
A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do payer contracts and reimbursement policies influence your biosimilar adoption decisions?
- How do you balance potential savings from biosimilars against operational costs of managing multiple products?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























